secwatch.observer — SEC 8-K summary
======================================

Issuer:     Absci Corp (ABSI)
CIK:        0001672688
Form:       8-K/A
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0001628280-25-039959
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 9.01, 2.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Absci Q2 2025 net loss $30.6M; raises $64M in July; Almirall collaboration expands
--------------------------------------------------------------------------------

- Q2 2025 revenue $0.6M (down from $1.3M YoY); net loss $30.6M vs $24.8M prior year.
- Cash, equivalents, and ST investments $117.5M at June 30; raised ~$64M in July, extending runway into H1 2028.
- Expanded Almirall AI drug discovery collaboration: second target elected, potential up to $650M in milestones across two programs.
- ABS-101 (anti-TL1A) Phase 1 interim readout expected H2 2025; ABS-201 (anti-PRLR) Phase 1/2a start early 2026.
- AMD strategic collaboration ongoing with $20M equity investment in Jan 2025; platform scaling using AMD Instinct accelerators.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672688/000162828025039959/0001628280-25-039959-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672688/000162828025039959/absc-20250812.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-039959

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer